McKesson reported fourth quarter fiscal 2026 revenues of $96.3 billion, a 6% increase year-over-year, with adjusted EPS growing 16% to $11.69. For the full fiscal year, revenues increased 12% to $403.4 billion, and adjusted EPS grew 18% to $39.11. The company introduced its fiscal 2027 adjusted EPS guidance in a range of $43.80 to $44.60, implying 12% to 14% growth.
Key Highlights
- The Oncology & Multispecialty segment was a key growth driver, with fourth quarter revenue increasing 35% year-over-year to $12.7 billion and adjusted segment operating profit rising 53%.
- McKesson announced a $5.0 billion increase to its share repurchase authorization, bringing the total to $7.7 billion, and entered into a $2.25 billion accelerated share repurchase program during the quarter.
- Full-year fiscal 2026 free cash flow was reported at $5.4 billion.